Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care

Authors
Publication date
1 December 2017
Publisher
'Springer Science and Business Media LLC'
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Crossref

      redirect
      oaiinfo:doi/10.1038%2Fs41408-017-...
      Last time updated on 04/12/2019
      Sustaining member

      Harvard University - DASH

      redirect
      oaioai:dash.harvard.edu:1/3501442...
      Last time updated on 17/04/2018
      Sustaining member

      University of Miami: Scholarship Miami

      redirect
      oaioai:alma.01UOML_INST:114144782...
      Last time updated on 16/01/2024